Olanzapine is used to treat schizophrenia.
In patients who respond to initial treatment, olanzapine is able to maintain its clinical effect during maintenance therapy.
Olanzapine is used to treat severe manic episodes.
Olanzapine may be used to preent relapse of bipolar disorder in patients with manic episodes who are responding to olanzapine therapy.
Usage and dosage:
Schizophrenia:
The recommended starting dose of olanzapine is 10mg/ day once daily, independent of eating.
In the course of the treatment of schizophrenia, the daily dose can be adjusted to 5 to 20mg/ day according to the clinical status of the patient, and it is recommended that after appropriate clinical evaluation, the dose should be increased to more than 10mg/ day, and the interval of dosing should not be less than 24 hours. Discontinuation of olanzapine should gradually reduce the dose.
Manic episodes:
The starting dose is 15mg daily when given alone and 10mg daily when combined
Preventing relapse of bipolar disorder:
The recommended starting dose is 10mg/ day, and for patients using olanzapine to treat a manic episode, the continuing treatment dose to prevent relapse is the same as before. For new episodes of mania, mixed episodes, or depressive episodes, olanzapine therapy should be continued (with appropriate dosage adjustments as needed), combined with adjuvant medications to treat emotional symptoms as clinically appropriate.
In the prevention and treatment of schizophrenia, manic episode and bipolar disorder, the daily dose can be adjusted in the range of 5-20mg/ day according to the individual clinical condition. It is recommended to use more than the recommended dose only after appropriate clinical reassessment, and the dosing interval is not less than 24 hours, and olanzapine is administered without consideration of feeding factors. Food does not affect absorption, and the dose should be gradually reduced during discontinuation of olazine.
Patients with impaired kidney and/or liver function:
A lower starting dose (5mg) should be considered for these patients. Patients with moderate hepatic insufficiency (cirrhosis, Child-pugh grade A or B) should receive a primary dose of 5mg and should be increased with caution.
Female patients compared to men:
The starting dose and dose range for female patients generally do not need to be adjusted.
Non-smokers compared to smokers:
The initial dose and dose range for non-smoking patients generally do not need to be adjusted.
When more than one metabolic slowing factor (female, older age, non-smoking) is present, a lower starting dose should be considered, and an increased dose should also be conservative.
Matters needing attention:
Hyperglycemia has rarely been reported, ketoacidosis or coma is rare in patients with a history of diabetes, and several deaths have been reported. Previous weight gain was reported in some cases, which may be a contributing factor, and appropriate clinical surveillance is recommended for both diabetics and those with high risk factors for diabetes.
The following acute symptoms, such as sweating, insomnia, tremors, anxiety, nausea, or vomiting (< 0.01%). It is usually recommended to gradually reduce the amount of olazine.
Audited Supplier 
){kind=link}
){kind=link}